HO-8910PM Cells Research Articles

Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1

Metastasis-suppressor genes, by definition, suppress metastasis without affecting tumorigenicity and, hence, present attractive targets as prognostic or therapeutic markers. BRMS1 (breast cancer metastasis suppressor) has recently been identified as a metastasis-suppressor gene for human breast cancer and melanoma. Expression of BRMS1 messenger RNA (mRNA) in multitissue including normal prostate, ovarian, testis, and colon has been detected by northern blot analysis. We hypothesize that the role of BRMS1 in tumor progression may not be limited to breast cancer and melanoma. We previously found that BRMS1 mRNA levels in primary ovarian epithelial carcinomas were significantly lower than that in normal ovarian and benign tumors (P < 0.05), and statistical analysis of BRMS1 mRNA levels revealed that BRMS1 mRNA levels were significantly higher in early tumor stages (I, II) compared with advanced tumor stages (III, IV) in which lymph node or distant metastases were present (P < 0.01). Our data showed that reduced BRMS1 mRNA seems to influence ovarian carcinoma metastatic ability. Therefore, we transfected BRMS1 plasmid into highly malignant ovarian carcinoma cell line, HO-8910PM, and examined cell biologic behaviors including proliferation, adhesion, invasion, and metastasis in vitro and in vivo. BRMS1 expression did not alter the proliferation of HO-8910PM cells in vitro and primary tumor formation in vivo. But, BRMS1 expression significantly suppressed the cell adhesion to extracellular matrix components and in vitro cell invasion in BRMS1-transfected HO-8910PM cells compared to parental HO-8910PM and vector-only transfectants (HO-8910PM-vect). Furthermore, motility of BRMS1 transfectants was inhibited. lung colony formation of intravenously injected BRMS1 transfectants in nude mice was significantly reduced. Also, BRMS1 transfectants form significantly less metastatic to organs of peritoneal cavity in orthotopically implanted ovarian tumor nude models. We further discovered that BRMS1 expression did downregulate expression of an actin-bundling protein associated with cell motility -fascin, which perhaps is the mechanism underlying BRMS1 suppression of metastasis. These data suggested that in addition to its already described role in breast cancer and melanoma, BRMS1 functions as a metastasis-suppressor gene in ovarian carcinoma by modifying several metastatic-associated phenotypes, offering a new target for therapeutic intervention.

The gene expression profile of highly metastatic human ovarian cancer cell line by gene chip

Objective: To study the gene expression of high metastatic human ovarian carcinoma cell line (HO-8910PM) and to screen for novel metastasis- associated genes by cDNA microarray. Methods: The cDNA was retro-transcribed from equal quantity mRNA derived from tissues of highly metastatic ovarian carcinoma cell line and normal ovarian, and was labeled with Cy5 and Cy3 fluorescence as probes. The mixed probes were hybridized with BioDoor 4096 double dot human whole gene chip. The chip was scanned by scanArray 3000 laser scanner. The acquired image was analyzed by ImaGene 3.0 software. Results: By applying the cDNA microarray we found: A total of 323 genes whose expression level were 3 times higher or lower in HO-8910PM cell than normal ovarian epithelium cell were screened out, with 71 higher and 252 lower respectively. Among these 10 were new genes. 67 genes showed expression difference bigger than 6 times between HO-8910PM cell and normal ovarian epithelium cell, among these genes 12 were higher, 55 lower, and two new genes were found. Conclusion: cDNA microarray technique is effective in screening the differentially expressed genes between human ovarian cancer cell line (HO-8910PM) and normal ovarian epithelium cell. Using the cDNA microarray to analyze of human ovarian cancer cell line gene expression profile difference will help the gene diagnosis, treatment and protection.

A study of multi-gene expression in the highly metastasizing human ovarian cancer cell line HO-8910PM and its mother cell line HO-8910

Objective: To investigate multi-gene expression in the highly metastasizing human ovarian cancer cell line HO-8910PM and its mother cell line HO-8910. Method: The expression of 9 kinds of gene products in HO-8910PM and its mother cell line HO-8910 was detected by S-P immunohistochemical method. Result: Eight kinds oncogene products showed various degrees of positive expression in both HO-8910PM and HO-8910 cell lines except gene bax. The expression of P53, Cyclin D1, CD44 v6 and EGFR in HO-8910PM was stronger than that in HO-8910. However, the expression of P16, nm23 in HO-8910PM was weaker than that in HO-8910. There was no significant difference on the expression of C-erbB-2 andbcl-2 between the two cell lines. Conclusion: Stronger invasive and metastatic patential is found in HO-8910PM than that in HO-8910. Carcinogenesis is a result of multi-oncogene and multiple step process cooperation.

P16 gene expression in ovarian epithelial cystadenocarcinoma

P16 gene expression was measured by immno-histochemical method in poor differentiated serous cystadenocarcinoma cell line, xenograft of highly metas-tasizing human ovarian carcinoma in nude mice and paraffin embedded tissues from 69 patients with ovarian carcinoma. The result showed that P16 gene was positive expression in HO-8910 cell of mother line, HO-8910PM cell line and xenograft of highly meatstasizing human ovarian carcinoma in nude mice. However, P16 gene in the metastatic cell had a weaker expression. P16 gene positive expression were also found in 51 cases of 69 cases (73.9%) in the ovarian epithelial carcinoma paraffin embedded tissues. Comparative studies showed that the positive rate of P16 gene expression markedly reduced with the increase of pathologic grade and clinical stage, metastasis in the lymph node and decrease of 5-year survival (P<0.05,P<O.Q1).